---
title: "\"Performance\" Abbott's revenue last quarter fell short of expectations, adjusting the full-year profit forecast"
description: "Abbott Laboratories announced that total revenue for the third quarter was $11.37 billion, slightly below the market expectation of $11.4 billion, as weakness in its diagnostics and nutrition business"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261293934.md"
published_at: "2025-10-15T14:26:57.000Z"
---

# "Performance" Abbott's revenue last quarter fell short of expectations, adjusting the full-year profit forecast

> Abbott Laboratories announced that total revenue for the third quarter was $11.37 billion, slightly below the market expectation of $11.4 billion, as weakness in its diagnostics and nutrition businesses offset strong demand for its medical devices; adjusted earnings per share were $1.30, in line with expectations. The company stated that it currently expects annual adjusted earnings per share to be between $5.12 and $5.18, compared to the previous expectation of $5.10 to $5.20

Abbott Laboratories (ABT.US) announced that total revenue for the third quarter was $11.37 billion, slightly below the market expectation of $11.4 billion, as weakness in its diagnostics and nutrition businesses offset strong demand for its medical devices; adjusted earnings per share were $1.30, in line with expectations.

The company stated that it currently expects annual adjusted earnings per share to be between $5.12 and $5.18, compared to the previous expectation of $5.10 to $5.20

### Related Stocks

- [ABT.US - Abbott Laboratories](https://longbridge.com/en/quote/ABT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Key facts: Exact Sciences to merge with Abbott by Q2 2026; 2025 revenue up 18% | Exact Sciences Corp. is merging with Abbott Laboratories, set to finalize in Q2 2026, pending approvals. The company als | [Link](https://longbridge.com/en/news/275986686.md) |
| Abbott Misses Third-Quarter Sales View, Narrows Full-Year Profit Outlook | Abbott Misses Third-Quarter Sales View, Narrows Full-Year Profit Outlook | [Link](https://longbridge.com/en/news/261305028.md) |
| Abbott misses revenue expectations on weak demand for diagnostic devices | Abbott's quarterly revenue of $11.37 billion fell short of analysts' expectations of $11.40 billion, primarily due to a  | [Link](https://longbridge.com/en/news/261249520.md) |
| Is the Market Bullish or Bearish on Abbott Laboratories? | Abbott Laboratories (NYSE:ABT) has seen a 14.02% decrease in short interest, with 15.88 million shares sold short, repre | [Link](https://longbridge.com/en/news/272305312.md) |
| Abbott Laboratories (NYSE:ABT) Director Daniel Starks Purchases 10,000 Shares | Abbott Laboratories (NYSE:ABT) Director Daniel Starks purchased 10,000 shares at an average price of $108.73, totaling $ | [Link](https://longbridge.com/en/news/275152686.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
